S100B and infection: Evaluation of MRKAd5 vaccine (gag/pol/nef) in the STEP (HVTN502) and Phambili (HVTN503) Phase IIb trials demonstrated induction of relatively strong and durable T cell responses (47, 55); however, in both studies, the vaccine failed to prevent infection or control early viremia in breakthrough infections.